Detalles de la búsqueda
1.
Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study.
Br J Cancer
; 129(11): 1780-1786, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37813959
2.
GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma.
J Neurooncol
; 147(3): 577-585, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32246395
3.
Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.
Pediatr Blood Cancer
; 65(6): e26967, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29350486
4.
Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models.
Cancers (Basel)
; 15(3)2023 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-36765861
5.
Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.
Cancers (Basel)
; 15(13)2023 Jun 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37444427
6.
Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy.
Cancers (Basel)
; 15(13)2023 Jun 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37444475
7.
The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD2 Antibody Dinutuximab Beta.
Cancers (Basel)
; 14(19)2022 Oct 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36230765
8.
Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments.
Cancers (Basel)
; 14(23)2022 Nov 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36497290
9.
Implementation of a combined CDK inhibition and arginine-deprivation approach to target arginine-auxotrophic glioblastoma multiforme cells.
Cell Death Dis
; 13(6): 555, 2022 06 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35717443
10.
BCL11B depletion induces the development of highly cytotoxic innate T cells out of IL-15 stimulated peripheral blood αß CD8+ T cells.
Oncoimmunology
; 11(1): 2148850, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36507091
11.
Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
Front Immunol
; 12: 690467, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34367149
12.
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy.
Front Pediatr
; 8: 582820, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33392114
13.
Reduction of CD11b+ myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD2 antibody ch14.18/CHO.
Oncoimmunology
; 9(1): 1836768, 2020 10 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-33150046
14.
Low CD4âº/CD25âº/CD127â» regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2.
Oncoimmunology
; 8(12): 1661194, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31741754
15.
Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice.
PLoS One
; 13(11): e0207320, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30452438
16.
Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.
Cancers (Basel)
; 10(10)2018 Oct 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-30336605
17.
PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO.
Oncoimmunology
; 6(10): e1343775, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29123953
18.
Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival.
Oncoimmunology
; 5(11): e1235108, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27999754
Resultados
1 -
18
de 18
1
Próxima >
>>